From: kristoff@NET.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 41, pt. 2, 13 November 1992
Date: 12 Nov 92 18:13:46 GMT
Distribution: bionet


$$XID NIHGUIDE 19921113 V21N41 P2O3 ************************************
stated in this RFA, awards will be administered under PHS grants policy
as stated in the Public Health Service Grants Policy Statement, DHHS
Publication No. (OASH) 90-50,000, revised October 1, 1990.

This RFA is a one-time solicitation.  However, if it is determined that
there is a sufficient continuing program need, the NCI will invite
recipients of awards under this RFA to submit competitive continuation
cooperative agreement applications for review according to the
procedures described in Review Considerations, Part A.

FUNDS AVAILABLE

Approximately $1,500,000 in total costs per year for four years will be
committed to specifically fund applications submitted in response to
this RFA.  It is anticipated that six to nine individual awards will be
made to one to three consortia.  This funding level is dependent on the
receipt of a sufficient number of applications of high scientific
merit.  The total project period for applications submitted in response
to the present RFA may not exceed four years.  Although this program is
provided for in the financial plans of the NCI, the award of
cooperative agreements pursuant to this RFA is also contingent upon the
continuing availability of funds for this purpose.

RESEARCH OBJECTIVES

The primary goal of this initiative is to stimulate clinical research
in the treatment of primary CNS malignancies in adult patients by
providing support for consortia of institutions to perform Phase I and
II clinical evaluations of promising new chemotherapeutic or biologic
agents.  A secondary goal is to utilize the consortia as a mechanism
for sharing human brain tumor specimens among investigators conducting
laboratory studies relevant to the biology, clinical behavior, or
therapy of CNS tumors, particularly malignant gliomas.

Clinical trials will take advantage of new developments in drug and
radiation resistance, radiation sensitization, biological response
modification, immune modulation, induction of apoptosis,
differentiation induction, therapeutic irradiation techniques,
induction or suppression of specific gene function, or other innovative
approaches.  Each CNSC will be formed for the purpose of:  (1) sharing
expertise of researchers in multiple disciplines; (2) conducting joint
phase I and II clinical trials to provide adequate patient populations
and timely completion; and (3) sharing of tumor specimens and data
useful in the conduct of clinical pharmacologic and correlative
laboratory studies.  Participant institutions in the proposed
consortium may be involved in clinical trials and/or laboratory
studies.

It is anticipated that one to three consortia will be established,
comprising three to nine institutions.  Each CNSC will select the
specific agents to be tested in accord with their scientific interest
and expertise and will develop a series of appropriate Phase II or
Phase I trials with supporting protocol documents.  Each applicant CNSC
should submit as examples one or more draft clinical protocols as
supplements to the Central Operations Office/Coordinating Center
(Project Leader) and the participant institution applications.  The
CNSC, along with the assistance of the NCI Program Director, will
develop a plan for prioritization of investigational trials.  The NCI
may provide NCI-sponsored IND agents or provide assistance to the
awardee(s) by sponsoring or cross-referencing INDs for selected agents.
Each CNSC must have documented numbers of patients with CNS tumors and
a history of accrual of patients to clinical trials adequate for
two-six phase I or II trials (60-180 patients) per year.  It is
expected that all of the CNSC institutions together will be able to
complete approximately six phase I or phase II trials (180 patients)
per year.  In addition, proposed consortia must have: (1) adequate
radiotherapy support for clinical trials utilizing radiation in
combination with other modalities; (2) adequate central data collection
and processing capabilities as well as biostatistical expertise; (3)
adequate pathology support for both institutional tumor classification
and central neuropathology review and for banking and distribution of
tumor tissues for concurrent and future laboratory studies; (4)
mechanisms to collect and store patient specimens for laboratory
studies being conducted by institutions in the CNSC; (5) expertise in
antineoplastic drug pharmacology/pharmacokinetics.

The correlative laboratory research program in a CNSC should address at
least one field of research into the biology of human malignant gliomas
with some potential for future clinical relevance.  Examples of
research fields for laboratory studies include:  molecular genetics and
cytogenetics, gene function and expression, signal transduction
pathways, radiobiology, growth regulation, metabolism, differentiation
and gene modulation by investigational agents, intracellular
metabolism, mechanisms of drug resistance in tumor cells, CNS
pharmacokinetics, invasion and spread, cytokine production or
interactions, immune function and antigen expression, or other aspects
that may have clinical implications or lead to new therapeutic
approaches.  Investigators are not limited to the above areas of
laboratory experimentation.

Correlative laboratory studies need not be directly related to
individual clinical Phase I/II trials but should attempt to utilize the
large clinical database that will be generated by the consortium to
identify potential correlates of tumor behavior, and laboratory studies
should be based on strong and testable hypotheses.  A clear rationale
should be given for the experimental design and technological
methodologies selected.  Preliminary data from appropriate tumor models
or analysis of patient specimens should be provided to support the
feasibility of each study.  The laboratory assays must utilize tumor
specimens from patients and there should be an established plan for
prioritization of specimen distribution to collaborating laboratories.
Participating institutions primarily involved in laboratory studies may
accrue patients on CNSC clinical trials if the minimum clinical
resources are in place (See ELIGIBILITY REQUIREMENTS).

The cooperative approach outlined in this RFA allows for interactions
among successful applicants, with the assistance of NCI extramural
staff, to perform Phase I and Phase II trials of anticancer agents and
ancillary laboratory studies.  This mechanism retains the
decision-making prerogatives of the Principal Investigator and his/her
colleagues, but at the same time, permits the active participation of
NCI in research activities.  (See TERMS OF COOPERATION)

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided. Applications without such
documentation will not be accepted for review.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.

All applications for clinical research submitted to NIH are required to
address these policies.  NIH funding components will not award grants
or cooperative agreements that do not comply with these policies.

LETTER OF INTENT

Prospective applicants are asked to submit, by January 15, 1993, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Project
Leader, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to which
the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
is helpful in planning for the review of applications.  It allows NCI
staff to estimate the potential review workload and to avoid conflict
of interest in the review.

The letter of intent is to be sent to Dr. Richard Kaplan at the address
listed under INQUIRIES.

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for cooperative agreements.  These forms are available at
most institutional offices of sponsored research; from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, Room 449, Westwood Building, 5333 Westbard Avenue, Bethesda, MD
20892, telephone (301) 496-7441; and from the NCI Program Director
named below.

The Central Operations Office/Coordinating Center as lead institution
should submit a research grant application in which they should list
the anticipated participant institutions, and include proposed clinical
protocols in the Appendix.  (The Central Operations Office/Coordinating
Center application must be a separate document from any application
from a participant institution; if a single institution will be
applying for both participation in clinical and/or laboratory studies
and as the Central Operations Office/Coordinating Center, two
applications will be necessary.)  Each participant institution should
submit an individual research grant application and should indicate the
Central Operations Office/Coordinating Center of the CNSC consortium in
which they intend to participate.  Participant institutions conducting
clinical trials should include copies of the proposed CNSC clinical
protocols in the Appendix.  The grant application should describe the
nature of their participation and justify budget requests for the
protocols.

Applications must be received by March 10, 1993.  If an application is
received after that date, it will be returned.  The Division of
Research Grants (DRG) will not accept any application in response to
this announcement that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application.
The DRG will not accept any application that is essentially the same as
one already reviewed.  This does not preclude the submission of
substantial revisions of applications already reviewed, but such
applications must include an introduction addressing the previous
critique.

REVIEW CONSIDERATIONS

Review Procedures

Upon receipt, applications will be reviewed for completeness by DRG and
responsiveness by the NCI.  Incomplete applications will be returned to
the applicant without further consideration.  Applications that are
judged non-responsive will be returned by the NCI.  An application
judged to be non-responsive to this RFA may be submitted as an
investigator initiated regular research grant (R01) or program project
grant (P01) at the next receipt date.  The application would require
modification in accordance with either the R01 or P01 guidelines.  The
new application would not be considered an application for a
Cooperative Agreement, nor would it be considered a response to an RFA.
Questions concerning the relevance of proposed research to the RFA may
be directed to program staff as described in the INQUIRIES section
below.

Applications may be triaged by an NCI peer review group on the basis of
relative competitiveness.  The NCI will withdraw from further
competition those applications judged to be noncompetitive for award
and notify the applicant and institutional business official.  Those
applications judged to be both competitive and responsive will be
further evaluated, using the review criteria stated below, for
scientific and technical merit by an appropriate peer review group
convened by the Division of Extramural Activities, NCI.  The second
level of review will be provided by the National Cancer Advisory Board.

AWARD CRITERIA

The anticipated date of award is September 1993.  In addition to the
technical merit of the application, NCI will consider how well the CNSC
and participant institutions met the goals and objectives of the
program as described in the RFA.

INQUIRIES

Written and telephone inquiries concerning the objectives and scope of
this RFA and inquiries about whether or not specific proposed research
would be responsive are strongly encouraged and may be directed to
program staff listed below.  The program staff welcome the opportunity
to clarify any issues or questions from potential applicants.

Direct inquiries regarding programmatic issues and requests for the RFA
to:

Dr. Richard Kaplan, Senior Investigator
Cancer Therapy Evaluation Program
National Cancer Institute
Executive Plaza North, Room 734
Bethesda, MD  20892
Telephone:  (301) 496-8866
FAX:  (301) 480-4663

Direct inquiries regarding fiscal matters to:

Ms. Katharine Schulze
National Cancer Institute
Executive Plaza South, Room 242
Bethesda, MD  20892
Telephone:  (301) 496-7800, ext. 16
FAX:  (301) 496-8601

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No 93.395, Cancer Treatment Research.  Awards are made under the
authorization of the Public Health Service Act, Title IV Sections 301,
410, and 411, Part A (Public Law 78-410, 42 USC 241 as amended, Public
Law 99-158, 42 USC 285a) and administered under PHS grants policies and
Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program
is not subject to the intergovernmental review requirements of
Executive Order 12372 or Health Systems Agency review.

$$R8 END ************************************************************

$$R9 BEGIN DK-93-06 FULL-TEXT ***************************************

EXPLORATORY GRANTS FOR CENTERS OF EXCELLENCE IN MOLECULAR HEMATOLOGY

NIH GUIDE, Volume 21, Number 41, November 13, 1992

RFA AVAILABLE:  DK-93-06

P.T. 34; K.W. 0785070, 1002058, 0780015, 1002045, 0760020, 1016003

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date:  January 31, 1993
Application Receipt Date:  March 15, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.  POTENTIAL
APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN INQUIRIES,
BELOW.

PURPOSE

The National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) invites applications for Exploratory Grants for Centers of
Excellence in Molecular Hematology, to be awarded competitively in
Fiscal Year 1993.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Exploratory Grants for Centers of Excellence in Molecular Hematology,
is related to the priority areas of diabetes and chronic disabling
conditions.  Potential applicants may obtain a copy of "Healthy People
2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy People
2000" (Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325 (telephone 202/783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted from domestic, for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, or medical centers.  Minority individuals and women are
encouraged to submit as Principal Investigators.  Applications from
foreign institutions are ineligible to apply.

MECHANISM OF SUPPORT

Support of this program will be through the NIH grant-in-aid
Exploratory Grant (P20) award.  Responsibility for the planning,
direction, and execution of the proposed project will be solely that of
the applicant.  Except as otherwise stated in this announcement, awards
will be administered under PHS grants policy as stated in the PHS
Grants Policy Statement.  The anticipated awards will be for one year
duration.  Requests for support must be limited to no more than $20,000
in direct costs.  Any application exceeding this amount will be
returned to the applicant.

FUNDS AVAILABLE

The NIDDK anticipates awarding five Exploratory Grants in Fiscal Year
1993 on a competitive basis, contingent upon the availability of
appropriated funds.  It is anticipated that approximately $150,000 in
FY 93 funds will be available for funding these awards.

RESEARCH OBJECTIVES

The objective of Exploratory Grants (P20) is to provide partial funding
for the cost of planning and developing meritorious future Centers of
Excellence in Molecular Hematology.  Centers of Excellence in Molecular
Hematology will allow development of the broad range of technologies
involved in investigation of genetic diseases and genetic therapy to be
brought together in a unified effort.  These technologies will draw on
knowledge of viruses, cell culture, bone marrow cells, growth factors,
animal models, and the molecular basis of genetic diseases.

During the past two decades, major advances have been made in
understanding the molecular basis for inherited diseases.  Application
of sensitive biochemical and molecular techniques has made molecular
diagnosis of a significant number of genetic disorders a reality.  Now,
with these important diagnostic achievements in hand, even greater
efforts must be directed toward development of technologies to
formulate specific therapies for these debilitating disorders.

The development of Centers as an organizational mechanism will promote
the joint efforts both of basic scientists and clinical researchers
toward the study of gene structure and function, the structural biology
of proteins and the complex biochemistry of protein interaction, the
cell and molecular regulation of blood cell formation, and clinical
research to test the efficacy and safety of therapeutic strategies
derived from basic investigation.  These studies will have as their
ultimate goal the development of somatic gene therapy or other means of
treatment of genetic diseases.

STUDY POPULATIONS

It is NIH policy that women and minorities must be included in clinical
study populations unless there is a good reason to exclude them, and
the study design must seek to identify any pertinent gender or minority
population differences.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided.  Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Potential applicants are strongly encouraged to submit a letter of
intent no later than January 31, 1993.  The letter of intent is to
include:  (1) name of the Principal Investigator/program director and
principal collaborators, (2) descriptive title of the potential
application, (3) identification of the organization(s) involved, and
(4) reference to RFA DK-93-06.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning the review of applications.  It
allows NIDDK staff to estimate the potential review workload and to
avoid conflict of interest in the review.

The letter of intent is to sent to:

Chief, Review Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Disease
Westwood Building, Room 605
Bethesda, MD  20892
Telephone:  (301) 496-7083

APPLICATION PROCEDURES

Applications are to submitted using form PHS 398 (rev. 9/91), available
in the business or grants offices of most academic or research
institutions and from the Office of Grants Inquiries, Division of
Research Grants, National Institutes of Health, 5333 Westbard Avenue,
Room 449, Bethesda, MD 20892, telephone 301-496-7441.  The RFA label
available in the PHS 398 application form must be affixed to the bottom
of the face page.  Detailed instructions on submission procedures are
described of the RFA.

REVIEW CONSIDERATIONS

Applications that are complete and responsive to the RFA will be
evaluated by an appropriate peer review group convened by the NIDDK in
accordance with the usual NIH peer review procedures.  Following
review, the applications will be given a secondary review by the NIDDK
Advisory Council unless not recommended for further consideration by
the initial review group.  Applications that are incomplete or
unresponsive to the RFA will be returned to the applicant.

AWARD CRITERIA

The anticipated date of award is September 30, 1993.  The criteria to
be used in the review of applications and the award of grants are
discussed in the RFA.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.
Direct inquiries about programmatic issues and request for copies of
the RFA to:

David G. Badman, Ph.D.
Hematology Program Director
Division of Kidney, Urologic and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05
Bethesda, MD  20892
Telephone:  (301) 496-7458

Direct inquiries regarding fiscal matters to:

Ms. Nancy Dixon
Grants Management Officer
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 637
Bethesda, MD  20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.849 for DKUHD.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR
Part 74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.

$$R9 END ************************************************************

                    ONGOING PROGRAM ANNOUNCEMENTS

$$P1 BEGIN PA-92-111 ************************************************

MINORITY HIGH SCHOOL STUDENT RESEARCH APPRENTICE PROGRAM

NIH GUIDE, Volume 21, Number 41, November 13, 1992

PA NUMBER:  PA-92-111

P.T. 34, FF; K.W. 0710030, 0720005

National Center for Research Resources

Application Receipt Date:  December 1, 1992

PURPOSE

The National Center for Research Resources (NCRR), National Institutes
of Health (NIH), currently plans to continue and expand the Minority
High School Student Research Apprentice Program (MHSSRAP) in 1993.  The
purpose of the program is to provide minority high school students with
a meaningful experience in various aspects of health-related research
in order to stimulate their interest in careers in science.

In FY 1993, the program is expanding the science teacher initiative to
include not only in-service elementary, middle, junior, and senior high
school teachers, but also potential K-12 science teachers in
pre-service education programs.  Eligible teachers will still be those
who are members of a minority group or who teach a significant number
of minority students.  Teachers may participate in the program for a
second year.  The hands-on summer research project must be structured
to update the teachers' knowledge and skills in modern research tools
and techniques as well as to strengthen their teaching skills.  The
experience should provide teachers the opportunity to bring back to the
classroom a sense of the excitement of research that would stimulate
students to pursue scientific careers.  A longer range goal is to
establish year round linkages between pre-service and in-service
science teachers, elementary and secondary school students, and
biomedical researchers.

Please note, however, that expansion of the program in FY 1993 is
contingent on the availability of appropriated funds.  Thus,
allocations may be reduced below the amount requested in the
application.  Upon recommendation of the National Advisory Research
Resources Council, the NCRR will give preference in making awards to
those institutions that can support a summer program having a "critical
mass" of at least five or six students.

ELIGIBILITY REQUIREMENTS

Eligible institutions are those that were eligible for a Biomedical
Research Support Grant award in FY 1992 or are awardees of the Minority
Biomedical Research Support (MBRS) Program.  ALL ELIGIBLE INSTITUTIONS,
INCLUDING THOSE NOT CURRENTLY OR PREVIOUSLY FUNDED UNDER THE MHSSRAP,
ARE STRONGLY ENCOURAGED TO APPLY.  Only one application for the
Apprentice Program may be submitted by a component of an institution
that is BRSG-eligible in FY 1992 and the recipient of an MBRS award.

Under-represented minority students and teachers are defined as
individuals who identify themselves as Black, Hispanic, Native
American, Pacific Islander, or any particular ethnic or racial group
which has been determined by the grantee institution to be
under-represented in biomedical or behavioral research.

Participants eligible for support must be U.S. citizens or have a
permanent visa.  Eligible students are those who are enrolled in high
school during the 1992-1993 academic year.  (Students who will graduate
from high school in 1993 are eligible, as is a student who participated
in a previous year provided he/she is still enrolled at the high school
level.)

MECHANISM OF SUPPORT

The mechanism of support for this program will be the NIH grant-in-aid
(S03).

Awards will be for one year beginning March 1, 1993, contingent upon
availability of appropriated funds.  Support will be provided at a
level of $2,000 for each student apprentice, $3,000 for each
pre-service teacher, and $5,000 for each in-service science teacher.
Applications may request both students and teachers or students only.
No indirect costs will be paid.  Direct support must be as salary;
stipends are not allowed.  Funds allocated may also be utilized for
supplies, extending the research experience, or if adequate funds
exist, for the addition of a student apprentice.  However, funds from
these grants may only be used for the costs of the apprentice program.
The Program Director is responsible for the recruitment and selection
of the apprentices and science teachers and assignment of each to an
appropriate investigator.

Students.  Recruitment and selection of students must emphasize factors
including the student's motivation, ability, scholastic aptitude, and
accomplishments.  In addition, consideration must be given to science
teachers' recommendations and, whenever possible, the degree of
parental commitment.  Assignments must be made to investigators
involved in health-related research who are committed to increasing the
high school student's understanding of research and the technical
skills needed.

Teachers.  Recruitment and selection criteria for in-service teachers
must include:  experience and teaching responsibilities, level of
interest in participating in a research program, expected impact on
their teaching programs, ability to stimulate minority students to
pursue scientific careers, and future plans for continued interaction
with the research institution.  Potential teachers should be enrolled
in pre-service programs and have an expressed interest in teaching life
sciences at the K-12 level.

APPLICATION PROCEDURES

The application consists of  (a) a letter stating the justification for
the number of student and teacher positions requested (preference will
be given to those institutions with a demonstrated commitment and a
documented history of encouraging students to pursue scientific
careers) and (b) the original and one signed and completed copy of the
face page, page 4 "Detailed Budget for First 12-Month Budget Period
Direct Costs Only," and checklist page of the grant application form
PHS 398 (rev. 9/91).  The required pages of the PHS 398 application
form must be completed according to instructions provided in the PHS
398 (rev. 9/91) kit except for the following:

Face Page

Item 1 - Leave blank.

Items 2a and 2b - Check the box marked "YES" and type in the number and
title of this Program Announcement.

Items 4 and 5 - Not applicable; do not complete.

Item 6, Dates of entire proposed project period - Enter 03-01-93
through 02-28-94.

Item 7 and 8 - Insert the total dollar amount of the request, which is
the sum, from application page 4, of the number of student positions
requested times $2,000 per student; the number of pre-service teachers
requested times $3,000; and the number of in-service teachers times
$5,000.  No indirect costs will be provided; thus the direct and total
costs will be the same.

Item 14, Organizational component to receive credit towards a
Biomedical Research Support Grant - Use this space to enter the code on
which eligibility for this MHSSRAP application is based (no credit will
be given for the S03 application).  Also use this space to enter the
BRSG and/or MBRS grant number(s) if available.

Page 4, "Detailed Budget for First 12-Month Budget Period Direct Costs
Only" - Using ONLY the Other Expenses category, enter on separate lines
the number of students requested at $2,000 per student; the number of
pre-service teachers requested at $3,000 per teacher; and the number of
in-service science teachers requested at $5,000 per teacher.

Enter the sum of the amounts requested for each under the "TOTALS"
column for the Other Expenses category and under "Total Direct Costs
for First 12-Month Budget Period" at the bottom of the page.

The original and one copy of the student and teacher report(s), signed
by the Program Director, must be submitted with the renewal application
by December 1 so that the data contained in these reports can be used
by NCRR to decide about policies and future funding for the MHSSRAP.

These reports must also be submitted at the same time even if renewal
support is not requested.  All reports, including the Financial Status
Report, must be submitted to the NIH by the grantee institution no
later than May 31, 1993, unless an extension of the budget period end
date has been authorized in writing.

Applications must be received by December 1, 1992 by:

Office of Grants and Contracts Management
National Center for Research Resources
Westwood Building, Room 849
5333 Westbard Avenue
Bethesda, MD  20892

(Do NOT mail the application to the Division of Research Grants, NIH.)

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Marjorie A. Tingle, Ph.D.
Director, Biomedical Research Support Program
National Center for Research Resources
Westwood Building, Room 10A-11
5333 Westbard Avenue
Bethesda, MD  20982
Telephone:  (301) 496-6743.

Direct inquiries regarding fiscal matters to:

Ms. Mary V. Niemiec
Office of Grants and Contracts Management
National Center for Research Resources
Westwood Building, Room 849
5333 Westbard Avenue
Bethesda, MD  20982
Telephone:  (301) 496-9840

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance, No. 93.337, Biomedical Research Support.  Grants will be
awarded under the authority of the Public Health Service Act, Section
301 (a)(3); Public Law 78-410 (42 USC 241) as amended, and administered
under PHS grants policies and Federal Regulations 45 CFR 74 and the
Guidelines for Minority High School Student Research Apprentice
Program.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.

$$P1 END ************************************************************

$$P2 BEGIN PA-93-016 ************************************************

MOLECULAR AND CELLULAR BIOLOGY OF METASTATIC TUMOR CELLS

NIH GUIDE, Volume 21, Number 41, November 13, 1992

PA:  PA-93-016

P.T. 34; K.W. 0715035, 1002004, 1002008

National Cancer Institute

PURPOSE

The National Cancer Institute (NCI) invites exploratory/developmental
grant applications to study the molecular and cellular biology of
metastatic tumor cells.  This special initiative is designed to promote
collaborations and facilitate scientific interchange between
investigators, one with experience in the biology of metastasis and the
other in a more basic scientific discipline such as molecular or
cellular biology, or biochemistry.  Therefore, prospective Principal
Investigators need to identify a research collaborator.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This Program
Announcement (PA), Molecular and Cellular Biology of Metastatic Tumor
Cells, is related to the priority area of cancer. Potential applicants
may obtain a copy of "Healthy People 2000" (Full Report: Stock No.
017-001-00474-0) or "Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325  (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by foreign and domestic, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Applications from minority individuals and women are encouraged.

MECHANISM OF SUPPORT

Support of this program will be through the National Institutes of
Health (NIH) exploratory/development research grant (R21).  Applicants
will be responsible for the planning, direction, and execution of the
proposed project.  Awards will be administered under PHS policy as
stated in the Public Health Service Grants Policy Statement, DHHS
Publication No. (OASH) 90-50,000, revised October 1, 1990 and in this
PA.

The Exploratory/Developmental Research Grants program (R21) provides
limited funds for short-term research projects.  These grants provide
an opportunity for initiating studies that may be preliminary in
nature.  Research investigators in relevant fields are invited to apply
for these grants in order to develop preliminary data that could form
the basis of future research project grant (R01) applications.

The Principal Investigator must be accountable to the recipient
organization officials for the proper conduct of the project.  The
research collaborator must be named and time and effort listed on the
budget page.  The recipient organization is legally responsible and
accountable to the PHS for performance and financial aspects of the
grant-supported activity.

FUNDS AVAILABLE

The direct costs per year for each application funded by the NCI must
not exceed $50,000.  The total project period for applications
submitted in response to this PA may not exceed two years and is not
renewable.  Applicants are advised to contact other relevant funding
components regarding their funding policies.

RESEARCH OBJECTIVES

The goal of this initiative is to provide funds for preliminary
research projects that will form the basis of future R01 applications
to investigate metastasis.  The intent is to (1) foster collaborative
research between investigators with basic molecular and cellular
biological and biochemical research experience, and those with
experience in metastasis research, and (2) increase the number of
laboratories and investigators addressing issues of metastasis.

The scope of the research may encompass the application of any aspect
of molecular and cellular biology and biochemistry to the investigation
of metastasis biology.  Applications should be for preliminary data
gathering or pilot feasibility studies, and should be founded on the
combined research experience of the Principal Investigator and his/her
collaborator.  The application should specifically address how the
application meets the intent of the initiative, e.g., the development
of a new collaboration between an investigator with basic molecular and
cellular biological and biochemical research experience and one with
experience in metastasis research.  Furthermore, the research
collaborator should address how the proposed research will relate to
and integrate with other ongoing research in his/her laboratory.  Just
as the initiative is intended to foster a research collaboration, the
application itself should clearly be the product of in-depth
discussions and input from both the research collaborator and the
Principal Investigator.

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these grants.  Applications will be accepted at the
three regular application deadlines as indicated in the application
kit.  These forms are available at most institutional offices of
sponsored research; from the Office of Grant Inquiries, Division of
Research Grants (DRG), National Institutes of Health, Room 449,
Westwood Building, 5333 Westbard Avenue, Bethesda, MD 20892, telephone
301/496-7441; from the NCI Program Director named below.  The title and
number of the PA must be typed in section 2a on the face page of the
application.

The completed original application and five exact copies must be sent
or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892

REVIEW PROCEDURE

Upon receipt, applications will be reviewed by the DRG for
completeness.  Incomplete applications will be returned to the
applicant without further consideration.  Those applications judged to
be complete will be further evaluated for scientific and technical
merit by study sections of the DRG.  Following the scientific and
technical review, the applications will receive a second level of
review by the appropriate national advisory council.

AWARD CRITERIA

Applications will compete for available funds with all other approved
applications.  The following factors will be considered when making
funding decisions:

o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the PA.

The following additional factors will be considered for applications
assigned to the NCI:

o  In order to increase the number of laboratories and investigators
with potential for a long-term commitment to metastasis research,
preference in funding will be given to those investigators that are
early in their research careers

o  The extent to which the proposed research develops collaborations
that address the purpose of the initiative

o  How the proposed research relates to and integrates with other
ongoing research in the research collaborator's laboratory

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic issues to:

Dr. Suresh Mohla
Chief, Cancer Biology Branch
National Cancer Institute
Executive Plaza South, Room 630
Bethesda, MD  20892
Telephone:  (301) 496-7028
FAX:  (301) 402-1037

Direct inquiries regarding fiscal and administrative issues to:

Robert Hawkins
Grants Management Branch
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD  20892
Telephone:  (301) 496-7800 ext. 13

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No.93.396, Cancer Biology.  Awards are under authorization of the
Public Health Service Act, Title, IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grant policies and Federal Regulations 42 CFR 52 and 45 CFR
Part 74.  This program is not subject to the intergovernmental review
requirements of Executive order 12372 or Health Systems Agency review.

$$P2 END ************************************************************

$$P3 BEGIN PA-93-017 ************************************************

OXIDATIVE DAMAGE, ANTIOXIDANT DEFENSE, AND AGING

NIH GUIDE, Volume 21, Number 41, November 13, 1992

PA:  PA-93-017

P.T. 34; K.W. 0710010, 0765035, 0760070, 0765025

National Institute on Aging

PURPOSE

Free radical damage has long been believed to be a risk factor for the
degenerative processes that accompany aging in a variety of animal
species ranging from insects to humans.  The free radical theory of
aging was proposed by Denham Harman in 1956, and much research since
then has been directed towards establishing correlations among
oxidative damage, antioxidant defense systems, aging and life span.
Although a few modest correlations have been observed, efforts to move
beyond correlative evidence, e.g., using antioxidant manipulations in
animal and cell culture models to attempt to extend maximum life spans,
have yielded few definitive results.  Nevertheless, evidence continues
to accumulate about the ubiquity of free radicals and their
considerable destructive potential in living tissues.  It is plausible
that an improved understanding of free radical processes will lead to
the discovery of interventions (dietary, pharmacological or genetic) to
improve health and increase life spans.  Research is needed to
establish the critical relationships among free radical sources,
protective systems and aging phenomena that may be amenable to
intervention.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by foreign and domestic, for-profit and
non-profit, public and private organizations, such as universities,
colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.
Applications from minority individuals and women are encouraged.

Foreign institutions are not eligible to apply for career awards (K04,
K08, K11) or First Independent Research Support and Transition (FIRST)
(R29) awards, and can apply for National Research Service Training
Awards (F32, F33) only if the applicant is a U.S. citizen.  Applicants
for F32, F33, K04, K08, and K11 awards must be U.S. citizens or
resident aliens.

MECHANISMS OF SUPPORT

The primary mechanisms for support of this program are:

o  Research grant (RO1)
o  FIRST award (R29)
o  Career grants, which include:  Research Career Development Award
(K04); Clinical Investigator Award (K08); Physician Scientist Award,
individual (K11)
o  Fellowships (F32, F33)

Deadlines for applications are as follows:

F-series grants:                            Jan 10, May 10, and Sep 10
New R and K-series grants:                  Feb 1, Jun 1, and Oct 1
Competing continuation and revised grants:  Mar 1, Jul 1, and Nov 1

RESEARCH OBJECTIVES

The National Institute on Aging (NIA) invites investigators to submit
applications for research on oxidative damage and pathobiology as
related to aging and the aging process.  Priority will be given to
research projects that are likely to provide critical insights into
these relationships other than correlative data.  Also, it is
recognized that the National Cancer Institute (NCI) has an interest in
the role of oxidative damage in cancer and the carcinogenesis process,
the National Institute of Environmental Health Sciences (NIEHS) has an
interest in toxic environmental agents, and the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) has an interest in
the role of oxidative damage due to saturated and unsaturated lipids on
normal and abnormal metabolic processes in high eukaryotes and humans.
Applications will be given an institute assignment based on the
Referral Guidelines for Funding Components of PHS.

The following areas of research are of particular interest to the NIA,
but applications need not be limited to the areas listed below.

1.  Improved methods for measuring any of the following in biological
tissues suitable for aging studies: levels of antioxidants in both the
oxidized and reduced state; rate of production of superoxide, hydrogen
peroxide and hydroxyl radical; levels and/or identification of oxidized
products in macromolecules, such as DNA, protein and lipids; rate of
repair of oxidized macromolecules in vivo.

2.  Identification of which enzyme activities involved in antioxidant
defense are rate-limiting, with particular emphasis on age-related
changes.

3.  The role of heavy metal ions, whether bound or free, in age-related
accumulation of oxidative damage in vivo.

4.  Development of interventions that reduce oxidative damage through
either neutralization of oxygen free radicals, reduction of the rate of
production of oxygen free radicals, repair of oxidative damage, or
improvement of antioxidant defense systems, coupled with a
demonstration that this reduced oxidative stress is associated with a
change in age-associated biological processes and/or diseases.

5.  The role of mitochondrial dysfunction in cellular oxidative damage
due to normal metabolism, and how this changes with age.

6.  Elucidation of how genes involved in antioxidant defense systems
are regulated in vivo, with particular emphasis on how the regulation
is altered during aging.

7.  The mechanism of attenuation of oxidative damage by spin trapping
compounds and other chemical and dietary interventions.

8.  Determination of whether and/or how caloric restriction reduces
oxidative damage, and whether or not this is related to life span
extension.

9.  The relationship between oxidative damage and the eventual
development of age-related disease states.

10.  Development of animal model systems, particularly transgenic
animals, to test the effect of altering
oxidative damage or antioxidant defense systems on aging and/or life
span.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities and women in
study populations so that research findings can be of benefit to all
persons at risk of the disease, disorder or condition under study;
special emphasis must be placed on the need for inclusion of minorities
and women in studies of diseases, disorders and conditions which
disproportionately affect them. This policy is intended to apply to
males and females of all ages.  If women or minorities are excluded or
inadequately represented in clinical research, particularly in proposed
population-based studies, a clear compelling rationale must be
provided.  The composition of the proposed study population must be
described in terms of gender and racial/ethnic group.  In addition,
gender and racial/ethnic issues should be addressed in developing a
research design and sample size appropriate for the scientific
objectives of the study.  This information must be included in the form
PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized
in Section 3, Recruitment of Individuals from Under represented
Racial/ethnic Groups, and Section 5, Human Subjects.  Applicants are
urged to assess carefully the feasibility of including the broadest
possible representation of minority groups.

However, NIH recognizes that it may not be feasible or appropriate in
ALL research projects to include representation of the full array of
United States racial/ethnic minority populations (i.e., Native
Americans including American Indians or Alaskan Natives, Asian/Pacific
Islanders, Blacks, Hispanics).  The rationale for studies on single
minority population groups must be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology, prevention
and preventive strategies, diagnosis, or treatment of diseases,
disorders or conditions, including but not limited to clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.  All applications for
clinical research submitted to NIH are required to address these
policies.  NIH funding components will not award grants or cooperative
agreements that do not comply with these policies.

APPLICATION PROCEDURES

Applications for R01, R29, and K Awards are to be submitted on the
grant application form PHS 398 (rev.9/91) and will be accepted at the
standard application deadlines indicated in the application kit.
Applications for F32 and F33 awards are to be submitted on form PHS 416
(rev. 10/91).

Application kits are available at most institutional offices of
sponsored research and may be obtained from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of Health,
Westwood Building, Room 449, Bethesda, MD 20892, telephone (301)
496-7441.  The title and number of the announcement must be typed in
Section 2a on the face page of the application.

The completed original application and five legible copies of PHS 398
or two copies of PHS 416 must be sent or delivered to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

To expedite the application's routing within the NIH, please check the
box on the face page of the application indicating that the application
is in response to this announcement and type (next to the checked box)
"Oxidative Damage and Aging."

Applications for F32, F33 and R29 awards must include at least three
letters of reference attached to the face page of the original
application.  Applications submitted without the required number of
reference letters will be considered incomplete and will be returned
without review.

REVIEW CONSIDERATIONS

The review criteria are the traditional considerations underlying
scientific merit.  Applications will be assigned on the basis of
established Public Health Service referral guidelines.  For information
on the special review criteria for the FIRST (R29) award, research
career awards (K series), and fellowships (F32, F33) contact the
program staff listed under INQUIRIES.  Applications will be assigned on
the basis of established PHS referral guidelines.  In accordance with
the standard NIH peer review procedures, research project grant (RO1
and R29) applications, fellowships (F32, F33) and research career
development awards (K04) will be reviewed for scientific and technical
merit by an appropriate study section in the Division of Research
Grants.  Other applications (K08 and K11) will be reviewed by an
appropriate institute review group.  Following scientific/technical
review, the applications will receive a second-level review by the
appropriate advisory council.

AWARD CRITERIA

There are no set-aside funds for funding these applications.
Applications compete for available funds on the basis of scientific
merit with all other applications.  The following will be considered in
making funding decisions:

o  Quality of the proposed project as determined by peer review
o  Availability of funds
o  Program balance among research areas of the announcement

INQUIRIES

Researchers considering an application in response to this announcement
may discuss their project and the range of grant mechanisms available
with NIA staff in advance of formal submission.  This can be done
either through a telephone conversation or a brief letter giving the
descriptive title of the proposed project and identifying the Principal
Investigator and, when known, other key participants.  Applications
related to the health of women and minorities are particularly
encouraged.  Correspondence and inquiries may be directed to:

Huber R. Warner, Ph.D.
Biology of Aging Program
National Institute on Aging
Gateway Building, Room 2C231
7201 Wisconsin Avenue
Bethesda, MD  20892
Telephone:  (301) 496-6402
FAX:  (301) 402-0010

or

Pamela Starke-Reed, Ph.D.
Geriatrics Program
National Institute on Aging
Gateway Building, Room 3E327
7201 Wisconsin Avenue
Bethesda, MD  20892
Telephone:  (301) 496-6761
FAX:  (301) 402-1784

Direct inquiries regarding fiscal matters to:

Joseph Ellis
Grants and Contracts Management Officer
National Institute on Aging
Gateway Building, Room 2N212
Bethesda, MD  20892
Telephone:  (301) 496-1472

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic Assistance
No. 93.866.  Awards are made under authorization of the Public Health
Service Act, Title IV, Part A (Public Law 78-410, as amended by Public
Law 99-158, 42 USC 241 and 285) and administered under PHS grants
policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74.  This
program is not subject to the intergovernmental review requirements of
Executive order 12372 or Health Systems Agency review.

$$P3 END ************************************************************

$$P4 BEGIN PA-93-018 ************************************************

NEURAL REGENERATION AND PLASTICITY AFTER SPINAL CORD INJURY

NIH GUIDE, Volume 21, Number 41, November 13, 1992

PA:  PA-93-018

P.T. 34; K.W. 0715027, 0705055, 1002030, 0760015

National Institute of Neurological Disorders and Stroke

PURPOSE

The Division of Stroke and Trauma (DST), National Institute of
Neurological Disorders and Stroke (NINDS), invites applications for
support of research that will increase our knowledge of the mechanisms
underlying the neuronal regeneration and plasticity that can follow
spinal cord injury.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This Program
Announcement (PA), Neural Regeneration and Plasticity after Spinal Cord
Trauma, is related to the priority area of unintentional injuries:
spinal cord injury.  Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report:  Stock No. 017-001-00474-0) or "Healthy
People 2000" (Summary Report:  Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington, DC
20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by foreign and domestic institutions,
for-profit and non-profit organizations, public and private, such as
universities, colleges, hospitals, laboratories, units of State and
local governments, and eligible agencies of the Federal government.
Applications from minority institutions, minority individuals, and
women are particularly encouraged.

MECHANISMS OF SUPPORT

The support mechanism for grants in this area will be the traditional
investigator-initiated research project grant (R01).  The Principal
Investigator will plan, direct, and, along with any co-investigators,
perform the research.  Applicants are encouraged to contact the NINDS
representative listed below as early as possible in the planning
stages.

RESEARCH OBJECTIVES

Background

Injury to the spinal cord tragically affects hundreds of thousands of
victims in the United States, with approximately 10,000 new traumatic
injuries each year.  Early treatment and improved hospital care have
increased survival, but at great cost.  The estimated yearly cost of
long term, specialized care for paralyzed patients exceeds $2 billion.
The personal costs to patients and their families is beyond
calculation: planned education, career, marriage, and independence are
interrupted and often never regained.

The spinal cord, as part of the central nervous system (CNS),
coordinates movement and sensation for the entire body below the head.
Specialized cell populations within the cord are the substrates for
these functions.  Large motoneurons extend long axons peripherally to
innervate skeletal muscle.  Extensive arborizations of these
motoneurons receive information via descending tracts from the brain.
The long fibers of dorsal root ganglion cells connect peripheral
sensory receptors to spinal interneurons, to motoneurons, and to brain
centers.  This complex neuronal circuitry of the spinal cord is
supported by the glia of the CNS.  Radial glia enclose the cord like
the rim and spokes of a wheel, defining compartments for ascending and
descending fiber systems.  Astrocytes contribute to the blood-spinal
cord barrier and provide a wide variety of support functions.
Oligodendrocytes myelinate axons.

Traumatic injury disrupts all of these cell types and changes their
functions.  Axons degenerate, neurons die, astrocytes proliferate and
become reactive, radial glia enclose large cysts, and oligodendrocytes
cannot remyelinate damaged areas.  The anatomy of an injured spinal
cord shows profound pathology, but also reveals the sprouting of
uninjured fibers, the regeneration of damaged populations, the
reorganization of glia, and clearing away of debris.

Enhancement of these beginnings of regeneration and reorganization is
necessary.  Several trophic factors are known to affect survival of
neurons and extension of neurites.  Likewise, naturally occurring
substances may enhance supportive glial functions.  Components of the
extracellular matrix can support the growth of axons.  The growing
knowledge of cellular mechanisms of repair within the injured spinal
cord offers the hope of treatment for this devastating disorder.

Research Goals and Scope

Examples of investigator-initiated research grant applications for
basic, applied, and clinical studies related to the understanding and
enhancement of regeneration in the injured spinal cord may include, but
should not necessarily be limited to:

o  identification of the tissues, cells, and substrates critical to the
regenerative process;

o  behavioral, chemical, functional, and structural correlates of
restored or remodeled neural circuits;

o  gene and protein expression in neurons and support cells during
regeneration;

o  development of cellular transplants to augment or support
regeneration, restore lost function, or replace damaged cells;

o  immune responses to implants of neural tissues, cell lines, or
cellular products; and

o  pharmacological or biochemical approaches to prolong or enhance
regeneration.

Applicants are encouraged to develop and use new or refined
methodologies, instrumentation, and procedures that will reveal
mechanistic details of the regenerative process.  Basic, applied, or
clinical studies on interventions or manipulations to improve regrowth
of fibers, prevent pathophysiological changes, or aid in functional
recovery are welcome.

POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements will be required to include minorities and women
in study populations so that research findings can be of benefit to all
persons at risk of the disease, disorder, or condition under study;
special emphasis should be placed on the need for inclusion of
minorities and women in studies of diseases, disorders, and conditions
that disproportionately affect them.  This policy is intended to apply
to males and females of all ages.  If women or minorities are excluded
or inadequately represented in clinical research, particularly in
proposed population-based studies, a clear compelling rationale should
be provided.

The composition of the proposed study population must be described in
terms of gender and racial or ethnic group.  In addition, gender and
racial or ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of the
study.  This information should be included in the form PHS 398 in
Sections 1-4 of the Research Plan AND summarized in Section 5, Human
Subjects.  Applicants are urged to assess carefully the feasibility of
including the broadest possible representation of minority groups;
however, the NIH recognizes that it may not be feasible or appropriate
in all research projects to include representation of the full array of
Unites States racial or ethnic minority populations:  Native Americans
(including American Indians or Alaska Natives), Asian or Pacific
Islanders, Blacks, and Hispanics).  The rationale for studies on single
minority population groups should be provided.

For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology, prevention
(and prevention strategies), diagnosis, or treatment of diseases,
disorders, or conditions, including, but not limited to, clinical
trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded; however,
every effort should be made to include human tissues from women and
racial or ethnic minorities when it is important to apply the results
of the study broadly.  This directive should be addressed by
applicants.

For foreign awards, the policy on inclusion of women applies fully.
Since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the review will be deferred until the information is provided.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the selected
study population is inadequate, it will be considered a scientific
weakness or deficiency in the study design and will be reflected in
assigning the priority score to the application.

All applications for clinical research submitted to the NIH are
required to address these policies.  NIH funding components will not
award grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURES

Applications are to be submitted on the grant application form PHS 398
(rev. 9/91) according to the instructions included in the application
package.  These application packages are available at the business
offices of most institutions eligible to receive Federal grants and
from the Office of Grants Inquiries, Division of Research Grants,
National Institutes of Health, Westwood Building, Room 449, Bethesda,
MD 20892, telephone 301/496-7441.

Receipt dates for new research project grant applications (R01) are
February 1, June 1, and October 1.

On page 1 of form PHS 398, check "yes" in Item 2a, enter the number of
this Program Announcement in the space provided, and provide the name
of this Program Announcement, Neural Regeneration and Plasticity after
Spinal Cord Injury in the blank space labeled "Title."

Use the mailing label provided in the application package to mail the
signed original and five exact copies of it to:

Division of Research Grants.
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

REVIEW CONSIDERATIONS

Applications will be reviewed for scientific and technical merit by an
appropriate study section in the Division of Research Grants.  The
second level of review will be by the appropriate national advisory
council.  The standard review criteria will be used to assess the
scientific merit of applications.

AWARD CRITERIA

Applications will compete for available funds with other applications
assigned to an Institute or Center.  The following will be considered
when making funding decisions:

o  quality of the proposed projects as determined by peer review
o  availability of funds
o  program balance among research areas.

INQUIRIES

Questions concerning scientific aspects of this Program Announcement
may be addressed to:

Dr. Mary Ellen Michel
Division of Stroke and Trauma
National Institute of Neurological Disorders and Stroke
Federal Building, Room 8A13
Bethesda, MD  20892
Telephone:  (301) 496-4226
FAX:  (301) 480-1080

Questions concerning fiscal aspects of this Program Announcement may be
addressed to:

Mr. King P. Bond, Jr.
Division of Extramural Activities
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
Bethesda, MD  20892
Telephone:  (301) 496-9231
FAX:  (301) 402-0219

AUTHORITY AND REGULATIONS

This program is described in the Catalogue of Federal Domestic
Assistance No. 93.853, Clinical Research Related to Neurological
Disorders, and No. 93.854, Biological Basis Research in the
Neurosciences.  Grants will be awarded under the authority of the
Public Health Service Act, Title IV, Section 301 (Public Law 78-410, as
amended: 42 USC 241) and administered under PHS grants policies and
Federal Regulations 42 CFR Part 52 and 45 CFR 74.  This program is not
subject to Health Services Agency Review of the intergovernmental
review requirements of Executive Order 12372.

$$P4 END ************************************************************

$$P5 BEGIN PA-93-019 ************************************************

NEUROLOGICAL BASIS OF RECURRENT HEADACHE, ESPECIALLY MIGRAINE

NIH GUIDE, Volume 21, Number 41, November 13, 1992

PA:  PA-93-019

P.T. 34; K.W. 0715138, 0765035, 0760025, 0755030, 0745027, 0411005

National Institute of Neurological Disorders and Stroke

PURPOSE

The Division of Stroke and Trauma (DST), National Institute of
Neurological Disorders and Stroke (NINDS), invites applications for
support of research that will increase our understanding of the causes
of, and add to our ability to treat and prevent, recurrent headache,
especially migraine.

ELIGIBILITY REQUIREMENTS

Applications may be submitted by foreign and domestic institutions,
for-profit and non-profit organizations, public or private, such as
universities, colleges, hospitals, laboratories, units of state and
local governments, and eligible agencies of the Federal government.
Foreign institutions are eligible to apply for research project grants
(R01) only.  Foreign institutions are not eligible for First
Independent Research Support and Transition (FIRST) (R29) awards.
Applications from minority institutions, minority individuals, and
women are particularly encouraged.

MECHANISMS OF SUPPORT

The support mechanisms for grants in this area will be the traditional
investigator-initiated research project grant (R01), the FIRST award
(R29), the program project grant (P01), and the center grant (P50).  As
consistent with the aforementioned mechanisms, the Principal